GVK-backed Oval Fertility launched in Hyderabad, eyes share in India's growing IVF market

GVK family-backed Oval Fertility has launched its first premium IVF center in Hyderabad, leveraging advanced embryo monitoring technology. Co-founded by US fertility specialist Dr. Brian Levine and Veena Reddy, the venture aims to redefine fertility care with a blend of science, technology, and personalized patient experience. The clinic, priced at Rs 4.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTjstYo
via IFTTT

Read More

FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

Wockhardt’s newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cAJZxhe
via IFTTT

Read More

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S8Y03QR
via IFTTT

Read More

Wockhardt secures US FDA approval for antibiotic Zaynich

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in India for similar infections and concurrent bacteremia, offering a significant solution to the growing threat of antimicrobial resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mrkbf30
via IFTTT

Read More

Molecule glue drugs shake up cancer care, draw big money

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l5uhT37
via IFTTT

Read More

Lincoln Pharmaceuticals posts Rs 11.63 crore profit for Q4

Lincoln Pharmaceuticals announced a slight profit rise for the fourth quarter ending March 31, 2026. Full fiscal year 2025-26 saw over 6 percent growth in consolidated net profit. Revenue from operations also increased year-on-year. The company's board recommended an 18 percent dividend. Lincoln Pharmaceuticals targets Rs 1,000 crore revenue in three years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/76Rj9yd
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6aAjqyO
via IFTTT

Read More